Financial StabilityCNS Pharmaceuticals has been able to raise approximately $15M, providing sufficient cash runway into the first half of 2025.
Management PerformanceManagement, over the past few years, has done a remarkable job, in our view, navigating the company through its most challenging period, which was compounded by both challenging biotech markets and a difficult financing environment in general.